Company intelligence / Profile preview

Curx Management

San Diego, California, United Statesthepharmaletter.com ↗

Ownership: Private
Development stage: Phase 1

Overview

CURx Pharmaceuticals was developing Captisol-enabled Topiramate Injection (IV topiramate) as a replacement therapy for certain emergent neurological conditions, including epilepsy, when oral administration is not feasible. New data was presented at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference in April 2024.

Therapeutic areas: PulmonologyNeurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Ligand PharmaceuticalsUniversity of Minnesota

Beyond the preview

Go deeper on Curx Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curx Management.

Explore the full profile